Induction of Cancer Testis Antigen Expression in Circulating Acute Myeloid Leukemia Blasts Following Hypomethylating Agent Monotherapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 18

PMID 26883197

Citations 44

Authors

Pragya Srivastava

Benjamin E Paluch

Junko Matsuzaki

Smitha R James

Golda Collamat-Lai

Nadja Blagitko-Dorfs

Laurie Ann Ford

Rafeh Naqash

Michael Lubbert

Adam R Karpf

Michael J Nemeth

Elizabeth A Griffiths

Affiliations

Soon will be listed here.

Abstract

Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

Citing Articles

BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism.

Yee C, Saxena K, Ryu E, Hung S, Singh S, Zhang Q Res Sq. 2024; .

PMID: 39711535 PMC: 11661303. DOI: 10.21203/rs.3.rs-5307127/v1.

Updates in novel immunotherapeutic strategies for relapsed/refractory AML.

Bawek S, Gurusinghe S, Burwinkel M, Przespolewski A Front Oncol. 2024; 14:1374963.

PMID: 39697225 PMC: 11652486. DOI: 10.3389/fonc.2024.1374963.

Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.

Ward G, Zhang Z, Jueliger S, Potapov I, Davis M, Boxall A Cancer Res Commun. 2024; 4(6):1441-1453.

PMID: 38727208 PMC: 11155518. DOI: 10.1158/2767-9764.CRC-23-0415.

Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.

Noronha N, Durette C, Cahuzac M, E Silva B, Courtois J, Humeau J Leukemia. 2024; 38(5):1019-1031.

PMID: 38627586 PMC: 11073987. DOI: 10.1038/s41375-024-02250-6.

The Expression Patterns of Human Cancer-Testis Genes Are Induced through Epigenetic Drugs in Colon Cancer Cells.

Almutairi M, Alrubie T, Almutairi B, Alamri A, Alrefaei A, Arafah M Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36355490 PMC: 9692864. DOI: 10.3390/ph15111319.

References

Coral S, Parisi G, Nicolay H, Colizzi F, Danielli R, Fratta E . Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother. 2012; 62(3):605-14. PMC: 11029398. DOI: 10.1007/s00262-012-1365-7. View

Akers S, Odunsi K, Karpf A . Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol. 2010; 6(5):717-32. PMC: 2896020. DOI: 10.2217/fon.10.36. View

Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. DOI: 10.1182/blood-2005-10-4149. View

Schuberth P, Jakka G, Jensen S, Wadle A, Gautschi F, Haley D . Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2012; 20(4):386-95. DOI: 10.1038/gt.2012.48. View

Doria-Rose V, Harlan L, Stevens J, Little R . Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program. Leuk Lymphoma. 2014; 55(11):2549-55. DOI: 10.3109/10428194.2014.885517. View

Wischnewski F, Pantel K, Schwarzenbach H . Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res. 2006; 4(5):339-49. DOI: 10.1158/1541-7786.MCR-05-0229. View

Kenderian S, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette J . CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015; 29(8):1637-47. PMC: 4644600. DOI: 10.1038/leu.2015.52. View

Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R . Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol. 2013; 92(3):195-203. DOI: 10.1111/ejh.12228. View

Corse E, Allison J . Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol. 2012; 189(3):1123-7. DOI: 10.4049/jimmunol.1200695. View

10.

Weber J, Vogelzang N, Ernstoff M, Goodman O, Cranmer L, Marshall J . A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011; 34(7):556-67. PMC: 3709852. DOI: 10.1097/CJI.0b013e3182280db1. View

11.

Gupta N, Miller A, Gandhi S, Ford L, Vigil C, Griffiths E . Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. Am J Hematol. 2015; 90(7):639-46. PMC: 6791130. DOI: 10.1002/ajh.24016. View

12.

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F . Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer. 2012; 132(11):2557-66. DOI: 10.1002/ijc.27939. View

13.

Fandy T, Herman J, Kerns P, Jiemjit A, Sugar E, Choi S . Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009; 114(13):2764-73. PMC: 2756131. DOI: 10.1182/blood-2009-02-203547. View

14.

Rowe J . Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program. 2009; :396-405. DOI: 10.1182/asheducation-2009.1.396. View

15.

Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C . Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res. 2012; 37(2):190-6. DOI: 10.1016/j.leukres.2012.10.015. View

16.

Khan A, Gregorie C, Tomasi T . Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2007; 57(5):647-54. PMC: 3146348. DOI: 10.1007/s00262-007-0402-4. View

17.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

18.

Woloszynska-Read A, Zhang W, Yu J, Link P, Mhawech-Fauceglia P, Collamat G . Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 2011; 17(8):2170-80. PMC: 3079045. DOI: 10.1158/1078-0432.CCR-10-2315. View

19.

Rao M, Chinnasamy N, Hong J, Zhang Y, Zhang M, Xi S . Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 2011; 71(12):4192-204. PMC: 3116976. DOI: 10.1158/0008-5472.CAN-10-2442. View

20.

Wang L, Mei Z, Zhou J, Yao Y, Li Y, Xu Y . Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One. 2013; 8(5):e62924. PMC: 3650049. DOI: 10.1371/journal.pone.0062924. View